Form 10-Q Annexon, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)
August 13, 2024 6:20 AM EDTH.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $30.00 price target on Annexon Biosciences (NASDAQ: ANNX).
The analyst comments "Valuation and Risks. Our price target of $30 is based on an equally weighted composite of: (a) $31.56/share, as a 30x multiple taxed and... More
